Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoTerminado
Patrocinadores
Assistance Publique - Hôpitaux de Paris

Palabras clave

Abstracto

The purpose of this study is to determine if patients with malignant middle cerebral artery infarction have a better clinical outcome after early decompressive surgery compared to standard medical management.

Descripción

The Decompressive Craniectomy In MALignant middle cerebral artery infarction (DECIMAL) trial is a prospective, multicenter, randomized, open (single blind for the evaluation of the primary outcome measure) controlled study of the efficacy of decompressive craniectomy plus the standard medical therapy as compared with the standard medical therapy alone in patients with a malignant middle cerebral artery infarction. The study protocol is approved by a regional ethic committee (CCPPRB Hospital SAINT LOUIS, PARIS). The study is conducted in 13 stroke centers in France and is funded by the French Ministry of Health and the "ASSISTANCE PUBLIQUE- HOPITAUX DE PARIS". An independent Data Safety Monitoring Board (DSMB) monitors the safety, progress and ethics of the trial.

The aim of the trial is to determine if patients with malignant middle cerebral artery infarction have a better clinical outcome after early decompressive surgery compared to standard medical therapy alone.

Secondary objectives are to determine clinical or MRI based prognostic factors of better outcome after decompressive surgery.

fechas

Verificado por última vez: 08/31/2007
Primero enviado: 09/12/2005
Inscripción estimada enviada: 09/12/2005
Publicado por primera vez: 09/18/2005
Última actualización enviada: 01/15/2008
Última actualización publicada: 01/16/2008
Fecha de inicio real del estudio: 11/30/2001
Fecha estimada de finalización primaria: 04/30/2006
Fecha estimada de finalización del estudio: 04/30/2006

Condición o enfermedad

Malignant Middle Cerebral Artery Infarction

Intervención / tratamiento

Procedure: A

Procedure: A

Fase

Fase 3

Grupos de brazos

BrazoIntervención / tratamiento
Experimental: A
HEMICRANIECTOMY
Procedure: A
Decompressive hemicraniectomy and duraplasty

Criterio de elegibilidad

Edades elegibles para estudiar 18 Years A 18 Years
Sexos elegibles para estudiarAll
Acepta voluntarios saludablessi
Criterios

Inclusion Criteria:

- Clinical and CT scan signs of complete infarction of the middle cerebral artery

- Onset of symptoms < 30 hours to a possible surgical intervention (< 24 hours for the inclusion and possibility to start treatment/surgery within 6 hours after randomisation)

- DWI infarct volume > 145 cm3

Exclusion criteria:

- The patients having a neurological pre existing handicap (score of Rankin sup or equal in 2).

- Patients having an ischaemia lateral against significant.

- Patients having a haemorrhagic transformation(conversion) sup in 50 % of the territory of the infarct.

- Patients having a severe co-morbidity with a reduced life expectation.

- Patients having a severe cardio-respiratory co-morbidity.

- Patients having antecedent of DUROPLASTIE with transplant of dura mater or transplant of cornea.

- Patients having a thrombolyses in 24 last hours.

- Patients having a severe coagulopathies.

- Patients having one against indication in the general anesthetic.

- Patients for whom a medical follow-up is not possible.

- The pregnant women.

- The patients to whom the surgical operation cannot be realized within 6 hours following the randomisation.

Salir

Medidas de resultado primarias

1. Primary endpoint: Functional outcome at 6 months [at 6 months]

Medidas de resultado secundarias

1. Secondary endpoints: [during the study]

2. Mortality [during the study]

3. Functional outcome at 9 and 12 months (mRS, NIHSS, Barthel-index) after stroke [at 9 and 12 months and after stroke]

4. Quality of life at 6 and 12 months (SIS) [at 6 and 12 months]

5. Complications related to surgery [during the study]

6. Infarct size at day 5-14 and week 12 and 48 [at day 5-14 and week 12 and 48]

7. Brainstem lesions on T2* after day 5-14 and week 12 and 48 [after day 5-14 and week 12 and 48]

Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge